Login Register Cart 0
Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Inhibitory Effect of Artemisinin on Testosterone Propionate Induced Benign Prostatic Hyperplasia

Author(s): Ayushi Solanki, Sandip Patel*, Nilay Solanki and Umang Shah

Volume 18, Issue 4, 2021

Published on: 12 June, 2020

Page: [518 - 524] Pages: 7

DOI: 10.2174/1570163817666200612151150

Price: $65

Abstract

Background: Benign prostate hyperplasia [BPH] is an abnormal growth of prostate observed commonly in elderly males. Artemisinin has been reported to reduce the levels of testosterone.

Objective: This study is designed to evaluate the efficacy of Artemisinin on testosterone propionate [TP] induced benign prostate hyperplasia.

Materials and Methods: Male Wistar albino rats [n=24] were separated into four groups of six rats each. Group I served as control and distilled water using tween 80 as an emulsifying agent was administered subcutaneously. BPH was induced by testosterone propionate 3mg/kg [Group II], S.C. daily for 28 days. Group III was BPH + Finasteride treated group (10mg/kg orally for 28 days) and BPH + Artemisinin treated group (Group IV) (50 mg/kg orally for 28 days).

Result: The study results showed significantly high levels of serum prostatic acid phosphatase (PAP), lactate dehydrogenase (LDH) and an elevation in prostate weight and prostatic index in Group II (BPH) when compared with Group I. The histopathological examination showed an increase in the epithelial proliferation of prostatic cells with involutions protruding into the lumen in BPH group when compared to the normal group. Treatment with Artemisinin (50 mg/kg) reduced the levels of PAP, LDH, prostate weight and prostatic index to a significant extent and restored the histoarchitectural features of the cells.

Conclusion: The present study concludes that Artemisinin is efficacious in testosterone propionate induced BPH. This could be attributed, at least partly, to its anti-inflammatory property or its role in testosterone level reduction or as a Vitamin D receptor modulator.

Keywords: Benign prostate hyperplasia, artemisinin, vitamin D receptor, testosterone, nutraceuticals, Vitamin D receptor modulator.

Graphical Abstract

[1]
Lim KB. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol 2017; 4(3): 148-51.
[http://dx.doi.org/10.1016/j.ajur.2017.06.004] [PMID: 29264223]
[2]
Nagarathnam M, Latheef S. Prevalence of lower urinary tract symptoms in patients of benign prostatic hyperplasia attending Tertiary Care Hospital in the State of Andhra Pradesh. J NTR Univ Health Sci 2017; 6: 154-7.
[http://dx.doi.org/10.4103/2277-8632.215533]
[3]
White CW, Xie JH, Ventura S. Age-related changes in the innervation of the prostate gland: implications for prostate cancer initiation and progression. Organogenesis 2013; 9(3): 206-15.
[http://dx.doi.org/10.4161/org.24843] [PMID: 23872639]
[4]
McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011; 185(5): 1793-803.
[http://dx.doi.org/10.1016/j.juro.2011.01.074] [PMID: 21420124]
[5]
Patel AK, Chapple CR. Benign prostatic hyperplasia: treatment in primary care. BMJ 2006; 333(7567): 535-9.
[http://dx.doi.org/10.1136/bmj.38946.616551.BE1] [PMID: 16960209]
[6]
Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res 2008; 20(Suppl. 3): S11-8.
[http://dx.doi.org/10.1038/ijir.2008.55] [PMID: 19002119]
[7]
Veeresh Babu SV, Veeresh B, Patil AA, Warke YB. Lauric acid and myristic acid prevent testosterone induced prostatic hyperplasia in rats. Eur J Pharmacol 2010; 626(2-3): 262-5.
[http://dx.doi.org/10.1016/j.ejphar.2009.09.037] [PMID: 19786012]
[8]
Manchanda PK, Kibler AJ, Zhang M, Ravi J, Bid HK. Vitamin D receptor as a therapeutic target for benign prostatic hyperplasia. Indian J Urol 2012; 28(4): 377-81.
[http://dx.doi.org/10.4103/0970-1591.105745] [PMID: 23450267]
[9]
Singh NP. Verma “Case report of a laryngeal squamous cell carcinoma treated with artesunate”. Arch Oncol 2002; 10(4): 279-80.
[http://dx.doi.org/10.2298/AOO0204279S]
[10]
Willoughby JA, Sundar SN, Cheung M, Tin AS, Modiano J, Firestone GL. Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. J Biol Chem 2009; 284(4): 2203-13.
[11]
Aprioku JS, Mankwe AC. Study on testicular response to prolong artemisinin-based combination therapy treatments in guinea pigs. Andrologia 2018; 50(2)e12852
[http://dx.doi.org/10.1111/and.12852] [PMID: 28752616]
[12]
Burk O, Arnold KA, Nussler AK, et al. Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol 2005; 67(6): 1954-65.
[http://dx.doi.org/10.1124/mol.104.009019] [PMID: 15761118]
[13]
Jena AK, Vasisht K, Sharma N, Kaur R, Dhingra MS, Karan M. Amelioration of testosterone induced benign prostatic hyperplasia by Prunus species. J Ethnopharmacol 2016; 190: 33-45.
[http://dx.doi.org/10.1016/j.jep.2016.05.052] [PMID: 27235020]
[14]
Arruzazabala ML, Más R, Molina V, Noa M, Carbajal D, Mendoza N. Effect of D-004, a lipid extract from the Cuban royal palm fruit, on atypical prostate hyperplasia induced by phenylephrine in rats. Drugs R D 2006; 7(4): 233-41.
[http://dx.doi.org/10.2165/00126839-200607040-00003] [PMID: 16784248]
[15]
Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin North Am 2011; 95(1): 87-100.
[http://dx.doi.org/10.1016/j.mcna.2010.08.013] [PMID: 21095413]
[16]
Reed D, Raina K, Agarwal R. Nutraceuticals in prostate cancer therapeutic strategies and their neo-adjuvant use in diverse populations NPJ Precision Oncology 2018; 2(1): 15.
[http://dx.doi.org/10.1038/s41698-018-0058-x]
[17]
Pagano E, Laudato M, Griffo M, Capasso R. Phytotherapy of benign prostatic hyperplasia. A minireview. Phytother Res 2014; 28(7): 949-55.
[http://dx.doi.org/10.1002/ptr.5084] [PMID: 25165780]
[18]
Bisson JF, Hidalgo S, Rozan P, Messaoudi M. Therapeutic effect of ACTICOA powder, a cocoa polyphenolic extract, on experimentally induced prostate hyperplasia in Wistar-Unilever rats. J Med Food 2007; 10(4): 628-35.
[http://dx.doi.org/10.1089/jmf.2006.242] [PMID: 18158833]
[19]
Jang H, Ha US, Kim SJ, et al. Anthocyanin extracted from black soybean reduces prostate weight and promotes apoptosis in the prostatic hyperplasia-induced rat model. J Agric Food Chem 2010; 58(24): 12686-91.
[http://dx.doi.org/10.1021/jf102688g] [PMID: 21121678]
[20]
Wright AS, Douglas RC, Thomas LN, Lazier CB, Rittmaster RS. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5α-reductase. Endocrinology 1999; 140(10): 4509-15.
[http://dx.doi.org/10.1210/endo.140.10.7039] [PMID: 10499505]
[21]
Banerjee S, Banerjee PP, Zirkin BR, Brown TR. Regional expression of transforming growth factor-alpha in rat ventral prostate during postnatal development, after androgen ablation, and after androgen replacement. Endocrinology 1998; 139(6): 3005-13.
[http://dx.doi.org/10.1210/endo.139.6.6060] [PMID: 9607812]
[22]
Jebor MA, Abood MR, Lilo RA. Biochemical changes in patients with benign prostate hyperplasia. Journal of University of Babylon 2014; 22(9): 2605-11.
[23]
Ejike CE, Ezeanyika LU. Inhibition of the experimental induction of benign prostatic hyperplasia: a possible role for fluted pumpkin (Telfairia occidentalis Hook f.) seeds. Urol Int 2011; 87(2): 218-24.
[http://dx.doi.org/10.1159/000327018] [PMID: 21709398]
[24]
Elhilali MM, Oliver JA, Sherwin AL, Mackinnon KJ. Lactate dehydrogenase isoenzymes in hyperplasia and carcinoma of the prostate: a clinical study. J Urol 1967; 98(6): 686-92.
[http://dx.doi.org/10.1016/S0022-5347(17)62958-6] [PMID: 4169732]
[25]
Schaeffer AJ, Wendel EF, Dunn JK, Grayhack JT. Prevalence and significance of prostatic inflammation. J Urol 1981; 125(2): 215-9.
[http://dx.doi.org/10.1016/S0022-5347(17)54976-9] [PMID: 7206060]
[26]
Wilson JD. The pathogenesis of benign prostatic hyperplasia. Am J Med 1980; 68(5): 745-56.
[http://dx.doi.org/10.1016/0002-9343(80)90267-3] [PMID: 6155068]
[27]
Penna G, Fibbi B, Amuchastegui S, et al. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate 2009; 69(5): 480-93.
[http://dx.doi.org/10.1002/pros.20896] [PMID: 19107880]

Rights & Permissions Print Cite
Article Metrics
35
1
© 2024 Bentham Science Publishers | Privacy Policy